[Translation] A clinical study of the efficacy and safety of Adasuve for the acute control of agitation in adult patients with schizophrenia or bipolar disorder

比较洛沙平吸入粉雾剂单量给药系统和安慰剂用于精神分裂症或双相障碍成人患者激越的急性控制有效性和安全性；

[Translation]

To compare the efficacy and safety of loxapine single-dose inhalation powder system with placebo for the acute control of agitation in adults with schizophrenia or bipolar disorder;

Start Date29 Apr 2020

Sponsor / Collaborator

Zhaoke Pharmaceutical (Hefei) Co., Ltd.

NCT03110900

/ TerminatedPhase 4IIT

A Randomized Double-blind Multicenter Double-dummy Non-inferiority Trial of Inhaled Loxapine and Intramuscular Haloperidol + Lorazepam for the Reduction of Agitation

The primary objective of this study is to determine the noninferiority of inhaled loxapine compared to intramuscular haloperidol/lorazepam on agitation reduction at 120 minutes.

Start Date30 Sep 2017

Sponsor / Collaborator

The University of Arkansas

[+1]

EUCTR2016-004884-38-ES

/ Not yet recruitingPhase 4IIT

Prospective naturalistic clinical trail with loxapine in agitated patients with personality disorder

Start Date13 Sep 2017

Sponsor / Collaborator

Vall d'Hebron University Hospital

100 Clinical Results associated with Loxapine

100 Translational Medicine associated with Loxapine

100 Patents (Medical) associated with Loxapine

954

Literatures (Medical) associated with Loxapine

01 May 2025·Acta Pharmacologica Sinica

Electrophysiological characterization of human KCNT1 channel modulators and the therapeutic potential of hydroquinine and tipepidine in KCNT1 mutation-associated epilepsy mouse model

Article

Author: Wang, En-Ze ; Wei, Yu-Ming ; Guo, Qing ; Zhang, Zhe ; Xu, Jie ; Tang, Qiong-Yao ; Cui, Meng ; Xu, Yun ; Jia, Meng-Xing ; Kong, Ming-Jian ; Gan, Jun ; Zhang, Fei-Fei

Patients suffering epilepsy caused by the gain-of-function mutants of the hKCNT1 potassium channels are drug refractory. In this study, we cloned a novel human KCNT1B channel isoform using the brain cDNA library and conducted patch-clamp and molecular docking analyses to characterize the pharmacological properties of the hKCNT1B channel using thirteen drugs. Among cinchona alkaloids, we found that hydroquinine exerted the strongest blocking effect on the hKCNT1B channel, especially the F313L mutant. In addition, we confirmed the antitussive drug tipepidine was also a potent inhibitor of the hKCNT1B channel. Subsequently, we proved that these two drugs produced an excellent therapeutic effect on the epileptic model of KCNT1 Y777H mutant male mice; thus, both could be ready-to-use anti-epileptic drugs. On the other hand, we demonstrated that the activation of the KCNT1 channel by loxapine and clozapine was through interacting with pore domain residues to reverse the run-down of the KCNT1 channel. Taken together, our results provide new insights into the mechanism of the modulators in regulating the KCNT1 channel activity as well as important candidates for clinical tests in the treatment of KCNT1 mutant-associated epilepsy.

01 May 2025·Clinical Pharmacology & Therapeutics

A 2024 Update on US FDA Implementation of Partial Area Under the Curve Into Bioavailability and Bioequivalence Assessments

Review

Author: Fang, Lanyan ; Newman, Bryan ; Stier, Ethan ; Uppoor, Ramana ; Hopefl, Robert ; Bielski, Elizabeth ; Zhang, Qiangnan ; Zhang, Lei ; Yoon, Miyoung ; Qin, Bin ; Gong, Yuqing ; Wang, Yan ; Pillai, Venkateswaran C ; Zhu, Hao

Comparisons of maximum drug concentration (Cmax) and total area under the concentration vs. time curve (AUC) may be inadequate for bioavailability (BA)/bioequivalence (BE) assessments in cases where the shape of the pharmacokinetic (PK) profile of a drug impacts the clinical performance. In such cases, partial area under the concentration vs. time curve (pAUC) has been recommended by regulatory agencies to support BA or BE assessments as a measure of drug exposure over specified time intervals of clinical relevance. This white paper serves as an update to the previously published white paper by Fang et al. at the US Food and Drug Administration (FDA), which introduced the general framework to provide pAUC recommendations. Since August 2020, 18 product‐specific guidances (PSGs) have been published or revised using the general framework to provide consistent, science‐ and risk‐based pAUC recommendations. Notable regulatory examples of pAUC applications discussed include loxapine inhalation powder, leuprolide long‐acting injectables (LAIs), and goserelin LAIs. This paper discusses recent applications of pAUC in the United States, highlights key examples of pAUC recommendations for regulatory applications, and provides insights about areas for global harmonization of pAUC recommendations.

01 Dec 2024·Journal of Medicinal Food

Investigating the Additive Effects of Loxacon^® Food Supplement Capsules in Patients with Knee Osteoarthritis. A Multicenter, Randomized, Double-Blind, Controlled, Crossover, Follow-Up, Three-Arm Study

Article

Author: Hodosi, K. ; Nemes, K. ; Bender, Tamas ; Gruber, Gy ; Somogyi, P. ; Gógl, Á. ; Sebők, E.

Osteoarthritis is one of the most common locomotor diseases, with a steadily increasing prevalence and incidence. Loxacon^® is a food supplement capsule containing vitamins, minerals, and herbal extracts with Boswellia serrata extract and Harpagophytum procumbens extract as its two main active components. The study involved 88 patients at 4 sites. The 88 patients were divided into 3 groups. The first group received physical therapy and Loxacon^® capsules for 5 weeks, while the second group (30 patients) received physical therapy only for 5 weeks, and the third group (30 patients) received physical therapy and placebo capsules for 5 weeks. After 5 weeks, physical therapy was discontinued in all three groups and all groups continued Loxacon^® capsules exclusively for an additional 60 days. Physical therapy had been carried out by a standard protocol over 5 weeks. Investigated parameters included Western Ontario and McMaster Universities Arthritis Index (WOMAC) testing, European Quality of Life (EQ-5D-5L) quality of life test and the Range of Motion (ROM). Among the 4 visual analogue scale (VAS) values investigated from WOMAC, significant change was seen for functionality in all three groups; however, the extent of change was twice as large in the physical therapy + Loxacon^® group at Visit 2 in comparison with the other two groups. In the physical therapy + placebo group, improvement was seen only at the 3rd visit when they were also receiving Loxacon^® capsules. The most pronounced difference was seen in the minimum clinically important difference index, calculated from the quality of life-VAS, where those taking Loxacon^® capsules had a chance 3 times as high to obtain clinical improvement versus the other two groups. Our study confirmed that a combination of boswellic acid and harpagosides is beneficial as an additional therapy in knee OA.

News (Medical) associated with Loxapine

29 Mar 2023

·www.biospace.com

IntelGenx Reports Fourth Quarter and Full-Year 2022 Financial Results

SAINT LAURENT, Quebec, March 29, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2022. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise. "The progress we made throughout 2022 has led us to now being potentially on the cusp of a stage of anticipated rapid growth,” commented Dr. Horst G. Zerbe, CEO of IntelGenx. “In April, we expect the FDA’s decisions on the Buprenorphine Buccal Film ANDA, as well as the RIZAFILM® NDA. On the development front, we are also looking forward to atai announcing topline results from its Phase 1 clinical trial of Buccal VLS-01, the first ever in-human clinical study evaluating an all thin film psychedelic drug candidate.” 2022 Fourth Quarter Financial Highlights: Revenue was $173,000, compared to $494,000 in the 2021 fourth quarter, mostly due to one-time licensing revenue received in 2021. Net comprehensive loss was $2.3 million, compared to $2.9 million in the 2021 fourth quarter. Adjusted EBITDA loss was $2.3 million, essentially unchanged from Q4-2021. 2022 Full-Year Financial Highlights: Revenue was $1.0 million, compared to $1.5 million in 2021, mostly due to one-time licensing revenue received in 2021. Net comprehensive loss was $11.6 million, compared to $9.8 million in 2021. Adjusted EBITDA loss was $8.5 million, compared to $7.1 million in 2021. Fourth Quarter and Recent Developments: Received a fourth and final term loan tranche in the amount of $3.0 million pursuant to the amended and restated secured loan agreement with the Company’s strategic partner, atai Life Sciences (“atai’). Closed a private placement offering of convertible notes due March 1, 2027 for aggregate gross proceeds of approximately $760,000 (C$1 million). Received from the U.S. Food and Drug Administration (‘FDA”) a Prescription Drug User Fee Act (PDUFA) goal date of April 17, 2023 for completion of the Agency’s review of the 505(b)(2) New Drug Application (“NDA”) for RIZAFILM® VersaFilm®. Participated in the 35th Annual ROTH Conference in Dana Point, California. Granted a Notice of Allowance for U.S. Patent Application 16/053,383, entitled "Loxapine Film Oral Dosage Form,” from the United States Patent and Trademark Office. Entered into a research collaboration with Per Svenningsson, MD, PhD, of the Karolinska Institute, to plan and conduct a multicentre, randomized, double-blind, placebo-controlled clinical study to investigate the use of Montelukast VersaFilm® for the treatment of Parkinson’s Disease. Entered into an exclusive supply agreement for RIZAPORT® with ARWAN Pharmaceuticals Industries Lebanon s.a.l. in various countries in the Middle East and North Africa region. Entered into a research collaboration with the University of Prince Edward Island to assess palatability, owner-perceived acceptability, and ease of administration of the Company’s VetaFilm™ platform in healthy dogs and cats. Financial Results: Total revenues for the three-month period ended December 31, 2022 amounted to $173,000, a decrease of $321,000, or 65%, compared to $494,000 for the three-month period ended December 31, 2021. The change is mainly attributable to decreases in revenues from licensing agreements of $249,000, R&D revenues of $43,000 and product revenues of $36,000, offset partially by an increase in royalties on product sales of $7,000. Operating costs and expenses were $2.7 million for the fourth quarter of 2022, versus $3.0 million for the corresponding three-month period of 2021. For Q4-2022, the Company had an operating loss of $2.5 million, essentially unchanged from the operating loss for the comparable period of 2021. Net comprehensive loss was $2.3 million, or $0.01 per basic and diluted share, for the fourth quarter of 2022, compared to net comprehensive loss of $2.9 million, or $0.02 per basic and diluted share, for the comparable period of 2021. Total revenues for the twelve-month period ended December 31, 2022 amounted to $1.0 million, representing a decrease of $585,000, or 38%, compared to $1.5 million for the year ended December 31, 2021. Operating costs and expenses were $10.4 million for the full year 2022, versus $9.5 million for the corresponding twelve-month period of 2021. For the twelve-month period of 2022, the Company had an operating loss of $9.4 million, compared to an operating loss of $8.0 million for the comparable period of 2021. Net comprehensive loss was $11.6 million, or $0.07 per basic and diluted share, for the twelve-month period of 2022, compared to net comprehensive loss of $9.8 million, or $0.07 per basic and diluted share, for the comparable period of 2021. As at December 31, 2022, the Company's cash and short-term investments totalled $2.5 million, which did not include the $3.0 million secured loan granted to IntelGenx Corp. by atai in January 2023, nor the $760,000 in gross proceeds from the private placement offering of convertible notes, which closed in March 2023. Annual Filings: The Company's annual report on Form 10-K and financial statements for the year ended December 31, 2022, as well as the 2023 Proxy Statement, will be filed with the United States Securities and Exchange Commission and the Canadian Securities regulatory authorities today, March 29, 2023. Conference Call Details: IntelGenx will host a conference call to discuss these 2022 fourth quarter and full year financial results today at 4:30 p.m. ET. The dial-in number for the conference call is (888) 506-0062 (Canada and the United States) or (973) 528-0011 (International); access code 884881. The call will be also be webcast live and archived on the Company's website at under "Webcasts" in the Investors section. About IntelGenx IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx’s superior film technologies, including VersaFilm®, DisinteQ™, VetaFilm™ and transdermal VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions. IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit . Forward-Looking Information and Statements This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at , and also filed with Canadian securities regulatory authorities at . IntelGenx assumes no obligation to update any such forward-looking statements. Source: IntelGenx Technologies Corp. For IntelGenx: Stephen Kilmer Investor Relations (647) 872-4849 stephen@kilmerlucas.com Or Andre Godin, CPA, CA President and CFO IntelGenx Corp. (514) 331-7440 ext 203 andre@intelgenx.com

Phase 1Financial Statement

29 Jun 2022

·www.biospace.com

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2022 and Provides Conference Call Information

Conference Call Scheduled for Thursday, June 30 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / June 29, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2022 ("Fiscal 2022"). Consolidated revenues for Fiscal 2022 were $32.3 million, an increase of $6.9 million or 27% as compared to the comparable period of the prior fiscal year. The increase was primarily attributed to revenues from generic immediate-release Adderall®, generic extended-release Adderall®, generic Loxapine Capsules, and strong revenues relating to Naltrexone Tablets sales. Operating profits were $5.1 million, an increase of $3.0 million from the comparable period of the prior year, and net income was $8.9 million. Conference Call Information Elite's management will host a conference call to discuss the year-end 2022 financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call. Date: June 30, 2022 Time: 11:30 AM EDT Dial-in numbers: 1-800-346-7359 (domestic) 1-973-528-0008 (international) Conference number: 98840 Questions: dianne@elitepharma.com Financial questions by 7:00 PM EST on Wednesday, June 29, 2022 Audio Replay: The financial statements can be viewed for Elite's Year 2022 on Form 10-K here. About Elite Pharmaceuticals, Inc. Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products which have been licensed to Lannett Company, Prasco, LLC, Epic Pharma, LLC, and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit . This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. Contact: For Elite Pharmaceuticals, Inc. Dianne Will, Investor Relations, 518-398-6222 Dianne@elitepharma.com SOURCE: Elite Pharmaceuticals, Inc. View source version on accesswire.com:

Financial Statement

29 Mar 2016

·www.biospace.com

Bay Area’s Alexza Pharma Reports Q4 Loss, Warns It May Shut Down

March 29, 2016 By Mark Terry , BioSpace.com Breaking News Staff Alexza Pharmaceuticals , headquartered in Mountain View, Calif., reported its fourth quarter and year-end financials yesterday, with a $3 million quarterly loss and a yearly net loss of $21.3 million. “We continue our efforts to increase the value of Adasuve, our pipeline and of Alexza,” said Thomas King , Alexza’s president and chief executive officer, in a statement. “In the last six months, we have decreased our costs, repositioned our management team, secured additional financing and continued to work with Guggenheim to explore strategic options.” The company believes it has enough capital to meet its cash needs until the end of April 2016. If it does not find more capital, it may have to shut down completely. Total revenues for 2015 were $5 million, down slightly from $5.6 million in 2014. In its conference call yesterday, King said, “Revenue in 2015 consists of three components. One, product sales from the units of Adasuve sold to Teva and Ferrer . Two, the amortization of the upfront payments received from Ferrer. And three, royalty revenue from Teva for the Adasuve sales in the United States.” Adasuve is used to agitation associated with schizophrenia or bipolar disorders. However, King stated in the call, “With commercial production completed, we suspended Adasuve production operation. We planned for Adasuve commercial production to resume in the future, as additional commercial product is required by our current or future partners.” He also indicated they may contract with third-party manufacturers if it was more efficient. GAAP operating expenses in the fourth quarter were $10.7 million, and for the year, $45 million. King also provided an update regarding a potential acquisition of the company by Barcelona, Spain-based Grupo Ferrer International . In February 2016, the two companies entered into a non-binding letter of intent for Ferrer to buy all of Alexza’s outstanding stock. In addition to working through the possible acquisition, the company is focused on partnering U.S. commercial rights for Adasuve. “It’s also clear that Adasuve works extremely well,” King said in the conference call, “in fact, perhaps even better than our clinical trials exhibited, as we’re not seeing and hearing the real world use of the product and receiving the feedback from physicians, clinicians, and nurses how it can significantly help patients. Physican by physician, patient by patient, caregiver by caregiver, Adasuve is changing medicine in treating these patients. This is very exciting and Adasuve is making a difference. At the same time, we appreciate the realities of where we are as a company and what strategic options might be available to us.” Alexza is currently trading for $0.52. Shares traded on April 7, 2015 for $2.07, dropped to $1.02 on May 19, rose slightly to $1.50 on Sept. 21, then plunged to $0.28 on Feb. 25, 2016. Shares recovered slightly to $0.74 on Mar. 24 before its most recent drop. Of the company, Investorplace wrote today, “ALXA investors are clearly nervous about the company’s ability to stay listed on the Nasdaq. The company has been in danger of delisting since Jun 2015, though it did receive a determination in March that it could stay on the Nasdaq should it comply with several minimum standards. One of these is a minimum $35 million market value by June 14 of this year—a now more difficult feat considering the company was worth $18 million before Tuesday’s 30 percent premarket haircut.”

AcquisitionFinancial StatementIPO

100 Deals associated with Loxapine

External Link

KEGG	Wiki	ATC	Drug Bank
D02340	Loxapine	N05AH01	DB00408

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Agitation	Iceland	Ferrer Internacional SA	20 Feb 2013
Agitation	Liechtenstein	Ferrer Internacional SA	20 Feb 2013
Agitation	European Union	Ferrer Internacional SA	20 Feb 2013
Agitation	Norway	Ferrer Internacional SA	20 Feb 2013
Bipolar Disorder	European Union	Ferrer Internacional SA	20 Feb 2013
Bipolar Disorder	Iceland	Ferrer Internacional SA	20 Feb 2013
Bipolar Disorder	Liechtenstein	Ferrer Internacional SA	20 Feb 2013
Bipolar Disorder	Norway	Ferrer Internacional SA	20 Feb 2013
Bipolar I disorder	United States	Alexza Pharmaceuticals, Inc.	21 Dec 2012
Schizophrenia	United States	Alexza Pharmaceuticals, Inc.	21 Dec 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bipolar Disorder	Preclinical	China	Zhaoke Pharmaceutical (Hefei) Co., Ltd.	29 Apr 2020
Schizophrenia	Preclinical	China	Zhaoke Pharmaceutical (Hefei) Co., Ltd.	29 Apr 2020
Asthma	Preclinical	United States	Alexza Pharmaceuticals, Inc.	01 May 2009
Agitation	Preclinical	United States	Alexza Pharmaceuticals, Inc.	01 Feb 2008
Psychotic Disorders	Preclinical	United States	Alexza Pharmaceuticals, Inc.	01 Oct 2007
Acute migraine	Preclinical	United States	Alexza Pharmaceuticals, Inc.	01 Jun 2007
Migraine Disorders	Preclinical	United States	Alexza Pharmaceuticals, Inc.	01 Jun 2007

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03110900 (loxapine, CTgov)	Phase 4	Drug intoxication \| Psychomotor Agitation \| Agitation	2	lorazepam+Haloperidol (Haloperidol + Lorazepam)	lqvhjzcitj(iuzvzfzpde) = yljsedsmqa dnequbmwor (htbcteeown, zihwhmecbf - qnfeerpjml) View more	-	11 Jun 2018
				Loxapine (Loxapine)	lqvhjzcitj(iuzvzfzpde) = qgvvsehwwu dnequbmwor (htbcteeown, xdhmbtaaig - qdwxboslxr) View more
NCT00369577 (CTgov)	Phase 2	Schizophrenia \| Agitation	129	Inhaled Placebo (Inhaled Placebo)	ubxkgomeuy(fdvdsywxbz) = skjcwueyeh ybxmhykxlw (qnfqdnrqxo, bahpegqaxp - rbzmlvcsox) View more	-	02 Jan 2018
				Inhaled Loxapine 5 mg (Inhaled Loxapine 5 mg)	ubxkgomeuy(fdvdsywxbz) = kltnovxxut ybxmhykxlw (qnfqdnrqxo, klxftgdiow - xwrstugksj) View more
NCT01193816 (Pubmed \| Crit Care)	Phase 4	Agitation	102	Loxapine	kjpktdcsgi(pobvwhjflw) = elytmvtyyy rhwouwnmch (waixsuhfwj )	-	06 Sep 2017
				Placebo	kjpktdcsgi(pobvwhjflw) = tdroudrurr rhwouwnmch (waixsuhfwj )
NCT00721955 (CTgov)	Phase 3	Bipolar I disorder \| Agitation	314	Inhaled Placebo (Inhaled Placebo)	(opqztxglsz) = cebqlrvytk orrknkajjd (wbetasylsm, eeuyuhbdcf - krahwujktd) View more	-	29 Jun 2017
				Inhaled loxapine 5 mg (Inhaled Loxapine 5 mg)	(opqztxglsz) = adogxgwnqj orrknkajjd (wbetasylsm, obuknotlzd - ezlofnryix) View more
NCT00628589 (CTgov)	Phase 3	Schizophrenia \| Agitation	344	Inhaled placebo (Inhaled Placebo)	cbhijiqypn(yhbtewdula) = yarpqybgpe jyqafnaeyt (wqrfibopta, wlxytvzkug - hyifvtmkhr) View more	-	29 Jun 2017
				Inhaled loxapine 5 mg (Inhaled Loxapine 5 mg)	cbhijiqypn(yhbtewdula) = qxgzxlletg jyqafnaeyt (wqrfibopta, rgkvgmcefn - vbeqgqfxkx) View more
NCT00825500 (CTgov)	Phase 2	Migraine Disorders	366	Inhaled Placebo (Inhaled Placebo)	wfplymvguf(vscgbjclqn) = pefphxftbc zytpuiyhxj (kxpofaxemc, bdnysicgnh - nfgynfqcwo) View more	-	24 Apr 2017
				Inhaled Loxapine 1.25 mg (Inhaled Loxapine 1.25 mg)	wfplymvguf(vscgbjclqn) = prnflbvwdm zytpuiyhxj (kxpofaxemc, nvahaejxpt - zravaheinz) View more
NCT00489476 (CTgov)	Phase 2	Migraine Disorders \| Acute migraine	168	Staccato Placebo (Staccato Placebo)	cqimegrrjc(pelzvfztwb) = bbdrdwejqm euimddtgyw (webgiyarpf, ikzcpkwayw - gxmzyvkyen) View more	-	24 Apr 2017
				Staccato Loxapine (1.25 mg Staccato Loxapine)	cqimegrrjc(pelzvfztwb) = psoysndcem euimddtgyw (webgiyarpf, zwbvaoxatv - dlmnrmbspj) View more
Pubmed \| J Clin Pharmacol	Not Applicable	-	-	loxapine aerosol 0.625 mg	fzjepoalie(xuqgdxiwvj) = nbkpzztpqh bkrpouihct (unyvnvndep )	-	01 Feb 2010
				loxapine aerosol 1.25 mg	fzjepoalie(xuqgdxiwvj) = nzzpwpearz bkrpouihct (unyvnvndep )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis